BLACKLEDGER Selling Watch: CCJ, UEC, VKTX
BLACKLEDGER's latest selling watch update tracks CCJ, UEC, VKTX, CRSP, BA, URG from the active public watchlist. This post is built from public-safe status data, in-house public signal labels, and outside public source context. It is designed to help readers understand what is happening around each asset without exposing private research methods.
Selling Watch Data
The dedicated feed category for this update is Selling. The latest public scan timestamp is 2026-09-11T08:00:05.798779+00:00.
- CCJ (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- UEC (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- VKTX (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- CRSP (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- BA (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- URG (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- LCID (stock): Bear public bias, Extended, public score 8.0/10, status: Paper trading research.
- OPEN (stock): Bear public bias, Extended, public score 8.0/10, status: Paper trading research.
Educational Context: How To Use This Page
This page is not a trade instruction. It is an educational research brief. Readers can use it to understand company or project background, public market context, public status labels, and relevant outside-source headlines before doing their own due diligence.
CCJ Public Research Bio
Name: Cameco Corporation. Market class: stock. Public bias: Bear. Public tier: Extended.
Cameco Corporation provides uranium for the generation of electricity in the Americas, Europe, and Asia. It operates in three segments: Uranium, Fuel Services, and Westinghouse. The Uranium segment engages in the exploration for, mining, milling, purchase, and sale of uranium concentrate. Its Fuel Services segment is involved in the refining, conve[redacted]on, and fabrication of uranium concentrate, as well as purchase and sale of conve[redacted]on services. The Westinghouse segment operates as a nuclear reactor technology original equipment manufacturer and a provider of products and services to commercial utilities and government agencies. It also provides outage and maintenance, engineering support, instrumentation and controls equipment, and plant modification services, as well as components and parts to nuclear reactors. The company sells its uranium and fuel products and services to nuclear utilities. Cameco Corporation was incor
- Latest public price/reference: $97.42
- Public market capitalization: $42.43B
- Recent public volume/reference: 2.03M
- One-month public movement: 10.42%
- Sector/category: Energy
Why CCJ Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Cameco (CCJ) Registers a Bigger Fall Than the Market: Important Facts to Note — Zacks
- Cameco vs. MP Materials: Which Crucial Renewable Energy Supplier Stock Is a Better Buy in 2026? — Motley Fool
- Cameco vs. TMC The Metals Co: Is a Uranium Stock or Rare Earth Metals Venture the Better Buy in 2026? — Motley Fool
- Energy Fuels Down 28% in the Past 6 Months: How to Play the Stock? — Zacks
UEC Public Research Bio
Name: Uranium Energy Corp.. Market class: stock. Public bias: Bear. Public tier: Extended.
Uranium Energy Corp., together with its subsidiaries, engages in exploration, pre-extraction, extraction, and processing of uranium and titanium concentrates properties in the United States, Canada, and the Republic of Paraguay. The company was formerly known as Carlin Gold Inc. and changed its name to Uranium Energy Corp. in January 2005. The company was incorporated in 2003 and is headquartered in Corpus Christi, Texas.
- Latest public price/reference: $11.02
- Public market capitalization: $5.45B
- Recent public volume/reference: 9.34M
- One-month public movement: 13.14%
- Sector/category: Energy
Why UEC Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Is Uranium Energy (UEC) a Buy as Wall Street Analysts Look Optimistic? — Zacks
- BWX Technologies Already Builds Reactors for the Navy. Why Is It Still the Cheapest Nuclear Stock? — Motley Fool
- Uranium Energy Rose as Jefferies Started Coverage — GuruFocus.com
- NuScale Advances Key Safety Component Toward SMR Commercialization — Zacks
VKTX Public Research Bio
Name: Viking Therapeutics, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystr
- Latest public price/reference: $32.13
- Public market capitalization: $3.75B
- Recent public volume/reference: 1.71M
- One-month public movement: -2.96%
- Sector/category: Healthcare
Why VKTX Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors — Zacks
- Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? — Motley Fool
- Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. — Motley Fool
- Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know — Zacks
CRSP Public Research Bio
Name: CRISPR Therapeutics AG. Market class: stock. Public bias: Bear. Public tier: Extended.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemog
- Latest public price/reference: $52.26
- Public market capitalization: $5.05B
- Recent public volume/reference: 1.26M
- One-month public movement: 7.89%
- Sector/category: Healthcare
Why CRSP Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue? — Zacks
- Why CRISPR Therapeutics Stock Rocked the Market Last Month — Motley Fool
- 3 Promising Genomics Stocks in the Spotlight in 2026 — Zacks
- Where Will CRISPR Therapeutics Stock Be in 5 Years? — Motley Fool
BA Public Research Bio
Name: The Boeing Company. Market class: stock. Public bias: Bear. Public tier: Extended.
The Boeing Company, together with its subsidiaries, designs, develops, manufactures, sells, services, and supports commercial jetliners, military aircraft, satellites, missile defense, human space flight and launch systems, and services worldwide. The company operates through three segments: Commercial Airplanes; Defense, Space & Security; and Global Services. The Commercial Airplanes segment develops, produces, and markets commercial jet aircraft for passenger and cargo requirements. The Defense, Space & Security segment engages in the research, development, production, and modification of manned and unmanned military aircraft and weapons systems; strategic defense and intelligence systems, which include strategic missile and defense systems, command, control, communications, computers, intelligence, surveillance and reconnaissance, cyber and information solutions, and intelligence systems; and satellite systems, such as government and
- Latest public price/reference: $204.8
- Public market capitalization: $161.87B
- Recent public volume/reference: 4.62M
- One-month public movement: -7.29%
- Sector/category: Industrials
Why BA Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Amazon’s Aviation Network Faces a Sobering Test after the Miami Crash — Insider Monkey
- Pump.fun Launches Custom Pairs for Tokenized Stocks — Bankless
- Boeing vs. GE Aerospace: Which Industrials Stock Is a Better Buy in 2026? — Motley Fool
- Boeing or Northrop? The Navy’s Next Fighter Race Is Down to the Wire. — Barrons.com
URG Public Research Bio
Name: Ur-Energy Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Ur-Energy Inc. engages in the acquisition, exploration, development, and operation of uranium mineral properties in the United States. It holds interests in 12 projects located in the United States. The company's flagship property is the Lost Creek project covering an area of approximately 1,800 unpatented mining claims and three Wyoming mineral leases covering an area of approximately 35,400 acres located in the Great Divide Basin, Wyoming. Ur-Energy Inc. was incorporated in 2004 and is headquartered in Littleton, Colorado.
- Latest public price/reference: $1.34
- Public market capitalization: $533.14M
- Recent public volume/reference: 4.36M
- One-month public movement: 7.2%
- Sector/category: Energy
Why URG Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Uranium Energy Stock Is Priced On Pounds It Has Not Sold Yet — Trefis
- From Yellowcake to Commercial Scale: Can Ur-Energy (URG) Live Up to Its Uranium Hype? — Insider Monkey
- Ur-Energy (URG) Q2 2026 Earnings Call Transcript — Motley Fool
- Ur-Energy Inc (URG) (Q2 2026) Earnings Call Highlights: Production Surges 47% as Shirley Basin ... — GuruFocus.com
What The Public Data Shows
The public feed highlights ticker status, market class, directional bias, score, tier, confidence, company or project profile, public market references, and outside-source headlines. These fields support a deeper view of BLACKLEDGER's public research feed while keeping private methods undisclosed.
Why This Category Matters
The Selling section gives readers a focused path through the market: buying watch content for constructive candidates, selling watch content for defensive movement, investing content for higher-quality public watch names, and market trend notes for broader context.
Research-Only Notice
BLACKLEDGER content is market research only. There is no live execution signal, no recommendation to buy or sell, and no financial advice. Readers should perform their own due diligence and consult licensed professionals before making financial decisions.
Research-only. No execution signal. Not financial advice.